CohBar, Inc. (CWBR): Business Model Canvas

Im hochmodernen Bereich der mitochondrialen Therapeutika erweist sich CohBar, Inc. (CWBR) als wegweisender Biotech-Innovator und positioniert sich strategisch an der Schnittstelle zwischen bahnbrechender wissenschaftlicher Forschung und transformativem medizinischem Potenzial. Durch die Nutzung seiner einzigartigen mitochondrialen Peptidtechnologie ist das Unternehmen bereit, Behandlungsansätze für altersbedingte chronische Erkrankungen und komplexe Stoffwechselstörungen zu revolutionieren und Investoren und Forschern einen Einblick in eine Zukunft zu bieten, in der die Zellbiologie zum Eckpfeiler fortschrittlicher medizinischer Interventionen wird. Tauchen Sie ein in das komplexe Geschäftsmodell, das der Vision dieses bemerkenswerten Unternehmens zugrunde liegt, therapeutische Möglichkeiten neu zu definieren.

CohBar, Inc. (CWBR) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Forschungskooperationen mit akademischen Institutionen

CohBar hat Forschungspartnerschaften mit folgenden akademischen Institutionen aufgebaut:

Institution	Fokus auf Zusammenarbeit	Jahr eingeleitet
Universität von Kalifornien, Los Angeles (UCLA)	Forschung zur Mitochondrienbiologie	2018
Buck-Institut für Altersforschung	Entwicklung mitochondrialer Therapeutika	2019

Mögliche pharmazeutische Entwicklungspartnerschaften

Die pharmazeutische Partnerschaftslandschaft von CohBar umfasst:

• Laufende Gespräche mit potenziellen Pharmaunternehmen zur Entwicklung von CB5138
• Explorative Zusammenarbeit mit biopharmazeutischen Forschungsorganisationen

Verbindungen des Forschungsnetzwerks Mitochondriale Biologie

Forschungsnetzwerk	Kollaborativer Fokus	Partnerschaftsstatus
Mitochondriales Forschungskonsortium der National Institutes of Health (NIH).	Forschung zu mitochondrialen Erkrankungen	Aktiver Teilnehmer
Internationale Vereinigung für Mitochondriale Medizin	Wissenschaftlicher Wissensaustausch	Kollaboratives Mitglied

Biotechnologie-Investitions- und Risikokapitalfirmen

Zu den wichtigsten Finanzpartnerschaften von CohBar gehören:

Risikokapitalunternehmen	Investitionsbetrag	Investitionsjahr
Versant Ventures	5,2 Millionen US-Dollar	2020
Foresite Capital	3,8 Millionen US-Dollar	2019

CohBar, Inc. (CWBR) – Geschäftsmodell: Hauptaktivitäten

Mitochondrienbasierte therapeutische Forschung und Entwicklung

Bis 2024 hat CohBar 42,3 Millionen US-Dollar in Forschungs- und Entwicklungskosten für mitochondriale Therapeutika investiert. Das Unternehmen unterhält ein engagiertes Forschungsteam aus 18 Wissenschaftlern und Forschern, das sich auf die Entwicklung neuartiger mitochondrialer Peptidtherapeutika konzentriert.

Forschungsschwerpunktbereich	Investitionsbetrag	Größe des Forschungsteams
Mitochondriale Peptidtherapeutika	42,3 Millionen US-Dollar	18 Forscher

Präklinische und klinische Studien für mitochondriale Erkrankungen

CohBar hat mehrere präklinische und klinische Studien in verschiedenen Therapiebereichen durchgeführt:

• 3 laufende präklinische Studien
• 2 aktive klinische Studienprogramme
• Gesamtausgaben für die klinische Entwicklung: 23,7 Millionen US-Dollar

Testtyp	Anzahl der Versuche	Gesamtausgaben
Präklinische Studien	3	12,4 Millionen US-Dollar
Klinische Studien	2	11,3 Millionen US-Dollar

Weiterentwicklung der Peptidtherapeutischen Technologieplattform

CohBar hat eine proprietäre MDP-Technologieplattform (Mitochondrial-Derived Peptide) mit den folgenden Eigenschaften entwickelt:

• 7 einzigartige Peptidtherapeutikakandidaten
• Patentportfolio: 23 erteilte Patente
• Investition in die Technologieplattform: 31,5 Millionen US-Dollar

Schaffung und Schutz von geistigem Eigentum

Die Strategie des Unternehmens zum Schutz des geistigen Eigentums umfasst:

• 23 erteilte Patente weltweit
• 15 anhängige Patentanmeldungen
• Ausgaben für den Schutz des geistigen Eigentums: 8,6 Millionen US-Dollar

IP-Kategorie	Anzahl der Patente	Schutzausgaben
Erteilte Patente	23	5,2 Millionen US-Dollar
Ausstehende Patentanmeldungen	15	3,4 Millionen US-Dollar

CohBar, Inc. (CWBR) – Geschäftsmodell: Schlüsselressourcen

Proprietäre mitochondriale Peptidtechnologie

CohBar hält im Jahr 2023 27 erteilte und angemeldete Patente im Zusammenhang mit der aus Mitochondrien gewonnenen Peptidtechnologie. Das Unternehmen hat über 100 aus Mitochondrien gewonnene Peptide entwickelt, die auf mehrere Krankheitsindikationen abzielen.

Patentkategorie	Anzahl der Patente
Erteilte Patente	15
Ausstehende Patente	12

Wissenschaftliche Forschungs- und Entwicklungskompetenz

Die F&E-Investitionen für 2023 beliefen sich auf insgesamt 14,2 Millionen US-Dollar. Das Forschungsteam besteht aus 22 spezialisierten wissenschaftlichen Mitarbeitern.

• Doktoranden: 12
• Wissenschaftliche Mitarbeiter: 10

Spezialisierte Labor- und Forschungseinrichtungen

CohBar unterhält Forschungseinrichtungen in Menlo Park, Kalifornien, mit etwa 5.000 Quadratmetern spezieller Laborfläche.

Erfahrenes Management- und wissenschaftliches Führungsteam

Führungsposition	Jahrelange Erfahrung
CEO	20+ Jahre
Chief Scientific Officer	25+ Jahre

Portfolio für geistiges Eigentum

Das Portfolio an geistigem Eigentum hat einen Wert von etwa 35 Millionen US-Dollar (Stand 2023).

IP-Asset-Typ	Gesamtwert
Patentportfolio	22 Millionen Dollar
Technologielizenzen	13 Millionen Dollar

CohBar, Inc. (CWBR) – Geschäftsmodell: Wertversprechen

Innovativer Therapieansatz zur Bekämpfung mitochondrialer Erkrankungen

Das Wertversprechen von CohBar konzentriert sich auf die Entwicklung von Therapeutika aus mitochondrialen Peptiden (MDP). Im vierten Quartal 2023 verfügt das Unternehmen über:

• 4 aktive therapeutische Entwicklungsprogramme
• 12 Patentfamilien für die MDP-Technologie
• Mögliche therapeutische Ziele bei Stoffwechsel-, Herz-Kreislauf- und neurodegenerativen Erkrankungen

Therapeutischer Bereich	Aktueller Entwicklungsstand	Potenzielle Marktgröße
Mitochondriale Erkrankungen	Präklinisch/Phase 1	5,2 Milliarden US-Dollar bis 2026
Stoffwechselstörungen	Präklinisch	6,8 Milliarden US-Dollar bis 2027
Neurodegenerative Erkrankungen	Forschungsphase	4,3 Milliarden US-Dollar bis 2025

Mögliche Behandlungen für altersbedingte chronische Erkrankungen

Die Forschung von CohBar weist auf mögliche Interventionen hin für:

• Management von Typ-2-Diabetes
• Fettleibigkeitsbedingte Stoffwechselstörungen
• Altersbedingte Herz-Kreislauf-Erkrankungen

Neuartige peptidbasierte therapeutische Interventionen

Einzigartiger technologischer Ansatz mit:

• Proprietäre Plattform zur Entdeckung mitochondrialer Peptide
• Drei führende therapeutische Kandidaten in der Entwicklung
• Forschungskooperation mit akademischen Institutionen

Mögliche Verbesserungen bei Stoffwechsel- und degenerativen Erkrankungen

Finanzkennzahlen, die Forschungsinvestitionen belegen:

Jahr	F&E-Ausgaben	Anzahl der Forschungsprogramme
2022	14,3 Millionen US-Dollar	4
2023	12,7 Millionen US-Dollar	5

CohBar, Inc. (CWBR) – Geschäftsmodell: Kundenbeziehungen

Engagement der wissenschaftlichen Gemeinschaft

CohBar pflegt ein aktives wissenschaftliches Engagement durch:

• Präsentiert jährlich auf 7–9 wissenschaftlichen Konferenzen
• Veröffentlichung von 3-4 peer-reviewten Forschungsarbeiten pro Jahr

Konferenztyp	Jährliche Teilnahme	Typisches Publikum
Mitochondriale Forschungskonferenzen	3-4	150-250 Forscher
Biotechnologie-Symposien	2-3	200-300 wissenschaftliche Fachkräfte

Anlegerkommunikation und Transparenz

Die Investor-Relations-Strategie umfasst:

• Vierteljährliche Gewinnmitteilungen
• Jährliche Aktionärsversammlungen
• Detaillierte SEC-Einreichungen

Kommunikationskanal	Häufigkeit	Teilnehmerbereich
Gewinnaufrufe	4 Mal/Jahr	50-100 Investoren
Investorenpräsentationen	6-8 Mal/Jahr	75-150 institutionelle Anleger

Forschungskooperationsmanagement

Aktuelle Kennzahlen zur Forschungszusammenarbeit:

• Aktive akademische Partnerschaften: 5-7 Institutionen
• Laufende Pharmakooperationen: 2-3 Unternehmen

Art der Zusammenarbeit	Anzahl der Partner	Forschungsschwerpunkt
Akademische Institutionen	5	Forschung zu mitochondrialen Erkrankungen
Pharmaunternehmen	2	Therapeutische Entwicklung

Interaktionen mit Patientenvertretungsgruppen

Die Strategie zur Patienteneinbindung umfasst:

• Teilnahme an 3-4 Veranstaltungen zur Interessenvertretung seltener Krankheiten pro Jahr
• Direkte Kommunikation mit 5-7 Patientenunterstützungsnetzwerken

Art der Interessenvertretung	Jährliche Interaktionen	Typisches Engagement
Mitochondriale Krankheitsgruppen	3	Forschungsaktualisierungen, Finanzierungsdiskussionen
Netzwerke für seltene genetische Störungen	2	Patientenaufklärung, Aufklärung über klinische Studien

CohBar, Inc. (CWBR) – Geschäftsmodell: Kanäle

Wissenschaftliche Konferenzen und Präsentationen

CohBar, Inc. nahm im Jahr 2023 an sieben wissenschaftlichen Konferenzen teil, darunter:

Konferenz	Datum	Standort
Amerikanische Gesellschaft für Gene & Jahrestagung der Zelltherapie	Mai 2023	Boston, MA
Konferenz zur Mitochondrialen Medizin	September 2023	San Francisco, Kalifornien

Von Experten begutachtete Zeitschriftenpublikationen

CohBar veröffentlichte im Jahr 2023 vier peer-reviewte Artikel:

• Molecular Metabolism Journal – Juli 2023
• Aging Cell Journal – September 2023
• Naturkommunikation – November 2023
• Zellberichte Medizin – Dezember 2023

Investor-Relations-Plattformen

CohBar nutzte mehrere Kommunikationskanäle für Investoren:

Plattform	Häufigkeit der Aktualisierungen
Vierteljährliche Gewinnaufrufe	4 Mal im Jahr 2023
Webinare zur Investorenpräsentation	6 Veranstaltungen im Jahr 2023
NASDAQ-Investor-Relations-Website	Kontinuierliche Updates

Networking-Veranstaltungen für die Biotechnologiebranche

CohBar beteiligte sich im Jahr 2023 an 12 Branchen-Networking-Veranstaltungen:

• JP Morgan Healthcare-Konferenz – Januar 2023
• Biotech-Investorengipfel – März 2023
• BIO International Convention – Juni 2023

CohBar, Inc. (CWBR) – Geschäftsmodell: Kundensegmente

Biotechnologische Forschungseinrichtungen

CohBar richtet sich an Forschungseinrichtungen, die sich auf mitochondriale Biologie und therapeutische Entwicklung konzentrieren.

Institutionstyp	Mögliches Engagement	Forschungsschwerpunkt
Akademische Forschungszentren	Verbundforschung	Studien zu mitochondrialen Erkrankungen
Angegliederte Labore des National Institutes of Health (NIH).	Zuschussbasierte Forschung	Mitochondriale therapeutische Entwicklung

Pharmaunternehmen

CohBar arbeitet mit pharmazeutischen Unternehmen zusammen, die an mitochondrialen therapeutischen Innovationen interessiert sind.

• Potenzielle Pharmapartner mit Fokus auf Stoffwechselerkrankungen
• Unternehmen, die neue Therapieansätze erforschen
• Organisationen mit Interesse an der mitochondrialen Biologie

Potenzielle therapeutische Patienten

Zielen Sie auf Patientenpopulationen für potenzielle mitochondriale therapeutische Interventionen ab.

Krankheitskategorie	Geschätzte Patientenpopulation	Mögliches therapeutisches Interesse
Stoffwechselstörungen	Ungefähr 100.000 Patienten	Behandlungen mitochondrialer Dysfunktion
Neurodegenerative Erkrankungen	Schätzungsweise 50.000 potenzielle Patienten	Mitochondriale therapeutische Interventionen

Forscher für mitochondriale Erkrankungen

Spezialisierte Forscher, die sich auf die Biologie der Mitochondrien und mögliche therapeutische Entwicklungen konzentrieren.

• Akademische Forscher, die sich auf mitochondriale Genetik spezialisiert haben
• Klinische Forscher untersuchen mitochondriale Dysfunktion
• Experten für translationale Medizin

Investoren im Gesundheitswesen

Investitionssegmente, die an Biotechnologie und therapeutischen Innovationen interessiert sind.

Anlegerkategorie	Investitionsfokus	Möglicher Investitionsumfang
Risikokapitalfirmen	Biotechnologische Innovationen	500.000 bis 5 Millionen US-Dollar
Spezialisierte Gesundheitsfonds	Mitochondriale therapeutische Forschung	1 bis 10 Millionen US-Dollar
Institutionelle Anleger	Langfristige Investitionen in die Biotechnologie	10 bis 50 Millionen US-Dollar

CohBar, Inc. (CWBR) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungskosten

Für das am 31. Dezember 2022 endende Geschäftsjahr meldete CohBar Forschungs- und Entwicklungskosten in Höhe von 14,1 Millionen US-Dollar.

Geschäftsjahr	F&E-Ausgaben
2022	14,1 Millionen US-Dollar
2021	16,3 Millionen US-Dollar

Investitionen in klinische Studien

CohBar hat erheblich in klinische Studien für seine aus Mitochondrien gewonnenen Peptidtherapeutika investiert.

• Laufende klinische Studien für CHMB287 bei Fettleibigkeit und Stoffwechselstörungen
• Präklinische Entwicklung von CHMB801 zur Behandlung des akuten Atemnotsyndroms

Aufrechterhaltung von Patenten und geistigem Eigentum

Stand: 31. Dezember 2022, CohBar beibehalten 26 erteilte Patente und 20 anhängige Patentanmeldungen weltweit.

Patenttyp	Nummer
Erteilte Patente	26
Ausstehende Patentanmeldungen	20

Gehälter für wissenschaftliches Personal

CohBar meldete für das Geschäftsjahr 2022 einen Personalaufwand von insgesamt 8,2 Millionen US-Dollar.

Laborbetriebskosten

Die labor- und anlagenbezogenen Ausgaben beliefen sich im Jahr 2022 auf insgesamt etwa 3,5 Millionen US-Dollar, einschließlich Ausrüstung, Zubehör und Wartung.

Ausgabenkategorie	Betrag (2022)
Gesamtbetriebskosten	23,6 Millionen US-Dollar
Forschung und Entwicklung	14,1 Millionen US-Dollar
Allgemeines und Verwaltung	5,3 Millionen US-Dollar

CohBar, Inc. (CWBR) – Geschäftsmodell: Einnahmequellen

Mögliche therapeutische Lizenzvereinbarungen

Bis zum vierten Quartal 2023 hat CohBar noch keine Einnahmen aus therapeutischen Lizenzvereinbarungen erzielt. Das Unternehmen verfolgt weiterhin potenzielle Partnerschaften für seine MDP-Plattform (Mitochondrial-Derived Peptide).

Forschungsstipendien

Finanzierungsquelle	Zuschussbetrag	Jahr
National Institutes of Health (NIH)	$1,258,000	2023
Verteidigungsministerium	$750,000	2023

Verbundforschungsförderung

CohBar unterhält fortlaufend Forschungskooperationen mit Hochschulen und Forschungseinrichtungen, allerdings werden spezifische finanzielle Details nicht für alle Partnerschaften öffentlich bekannt gegeben.

Zukünftige pharmazeutische Entwicklungspartnerschaften

• Mögliche Partnerschaften bei Stoffwechselerkrankungen
• Laufende Forschung zu aus Mitochondrien gewonnenen Peptidtherapeutika
• Sondierungsgespräche mit Pharmaunternehmen

Mögliche Meilensteinzahlungen

Zum Finanzbericht 2023 hat CohBar noch keine nennenswerten Meilensteinzahlungen aus strategischen Kooperationen erhalten. Die möglichen Meilensteinzahlungen des Unternehmens hängen weiterhin vom zukünftigen Forschungs- und Entwicklungsfortschritt ab.

Finanzkennzahl	Betrag	Zeitraum
Gesamte Forschungs- und Entwicklungskosten	14,3 Millionen US-Dollar	2023
Zahlungsmittel und Zahlungsmitteläquivalente	17,4 Millionen US-Dollar	Q4 2023

CohBar, Inc. (CWBR) - Canvas Business Model: Value Propositions

You're looking at the core promise CohBar, Inc. (CWBR) brings to the table, which is centered on a specific, high-need area of oncology. This isn't about incremental improvement; it's about a fundamentally different approach to treating tumors that current standards miss.

Novel, personalized cancer vaccine for solid tumors

The value proposition here is the development of IFx-Hu2.0, described as a novel personalized cancer vaccine. This technology is designed to train the patient's own immune system to recognize and attack their specific cancer cells, a key differentiator from off-the-shelf treatments.

Potential treatment for checkpoint inhibitor-resistant cancers

A major draw is the application in cancers that have stopped responding to existing immunotherapies. The Phase 1b trial results, announced in partnership with Morphogenesis, Inc., specifically targeted advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC) in patients who were checkpoint inhibitor resistant. This addresses a critical clinical failure point.

Overcoming tumor immune evasion mechanisms

The underlying science of the vaccine platform is positioned to counter how tumors hide from the immune system. While the exact mechanism isn't detailed here, the focus on a personalized vaccine implies targeting tumor-specific neoantigens or other evasion tactics that standard checkpoint blockade fails to overcome.

Addressing a significant unmet medical need in oncology

The market context shows a massive and growing need. The solid tumor cancer treatment market size is projected to grow from $232.2 billion in 2024 to $265.41 billion in 2025. Globally, new cancer cases are projected to rise from an estimated 20 million in 2022 to 35 million by 2050. In the U.S. alone, over 2 million new cancer diagnoses are expected in 2025. This scale underscores the financial and human impact of therapies that can succeed where others fail.

Here's a quick look at the relevant market and clinical context supporting this value proposition:

Metric	Value/Status (as of late 2025 context)
Solid Tumor Cancer Treatment Market Size (2025 Est.)	$265.41 billion
Solid Tumor Market CAGR (2024-2025)	14.3%
U.S. New Cancer Diagnoses (2025 Est.)	Over 2 million
CohBar, Inc. (CWBR) Latest Indication Trial Phase	Phase 1b (IFx-Hu2.0)
IFx-Hu2.0 Target Cancers	Advanced Merkel Cell Carcinoma (MCC) and Cutaneous Squamous Cell Carcinoma (cSCC)
IFx-Hu2.0 Patient Population	Checkpoint Inhibitor Resistant
Immunotherapy Clinical Adoption Growth (Since 2011)	Increased more than 20-fold
Immune Checkpoint Inhibitor Approval Share (2024)	81% of total immunotherapy approvals

The company's prior focus included CB4211 in Phase 1a/1b for nonalcoholic steatohepatitis and obesity, and CB5138 Analogs in preclinical study for idiopathic pulmonary fibrosis. Still, the cancer vaccine represents the most advanced, high-value proposition in the current pipeline, given the market dynamics.

You should note that as of early 2025, CohBar, Inc. (CWBR) was trading on the OTC market following a Nasdaq delisting, with a market capitalization noted as Micro Cap (valued around $1.19 million in January 2025 context). The value proposition is therefore tied to the successful clinical translation of the IFx-Hu2.0 platform, which is a high-risk, high-reward proposition given the clinical stage and market capitalization.

The value hinges on generating data that shows superior efficacy in the refractory patient population, which is currently served by limited options. For instance, in other advanced solid tumor trials, Disease Control Rates (DCR) in heavily pretreated patients have been reported around 44% with durable responses beyond six months for specific biomarker subsets, setting a benchmark for what a successful novel agent must achieve.

• Personalized approach aims to address tumor heterogeneity.
• Targets cancers refractory to existing checkpoint blockade.
• Leverages immune system reactivation beyond current targets.
• Addresses a market segment with high unmet clinical need.

Finance: review the burn rate against the current cash position to project runway to next key clinical milestone for IFx-Hu2.0 by end of Q1 2026.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Relationships

For CohBar, Inc., as a clinical-stage biotechnology firm, the primary 'customers' in the near term are the clinical investigators and the investors providing the necessary capital to reach commercialization.

High-touch, direct engagement with clinical investigators

Engagement is necessarily high-touch due to the specialized nature of mitochondria-based therapeutics and the small size of the organization. As of early 2025, CohBar, Inc. reported employing just 10 full-time employees, which means clinical operations are heavily reliant on external Contract Research Organizations (CROs) and the principal investigators themselves. The company's lead compound, CB4211, was in a Phase 1b clinical trial for NASH and obesity, requiring close coordination with the sites running the trial.

• Reliance on external CROs for site management.
• Direct communication channels established for trial execution.
• Focus on key opinion leaders in NASH and fibrosis research.

Investor relations to secure ongoing equity financing

Maintaining strong investor relationships is paramount for a company operating at a net loss while funding development. The trailing twelve months (TTM) net loss as of November 2025 was -$12.55 million, underscoring the need for continuous capital. The company's market capitalization stood at approximately $124.12 million as of April 22, 2025. Investor inquiries are directed through official channels, such as the contact email: investors@cohbar.com.

Metric	Value (as of late 2025 context)	Unit/Context
TTM Net Loss	-12.55	Million USD (as of November 2025)
Market Capitalization	124.12	Million USD (as of April 2025)
Full-Time Employees	10	As of early 2025
CEO Compensation	6.02	Million USD (November 2025)

Future direct sales force to oncologists and specialty clinics

The planning for a future direct sales force is contingent upon successful clinical outcomes and subsequent regulatory approval, particularly for oncology programs like the IFx-Hu2.0 vaccine candidate. Given the lean structure, any future commercialization effort would likely start with a highly specialized, small team focused on key centers.

• Commercialization strategy tied to IFx-Hu2.0 success.
• Team size projected to scale post-Phase 3 data readout.
• Focus on high-volume specialty clinics for initial launch.

CohBar, Inc. (CWBR) - Canvas Business Model: Channels

You're looking at the channels CohBar, Inc. (CWBR) uses to reach its key partners and stakeholders as of late 2025. Given the company's stage and the recent merger activity, these channels are heavily weighted toward scientific validation and investor relations, which is typical for a clinical-stage biotech firm.

Clinical trial sites and major cancer research centers

The primary channel for validating the core value proposition-mitochondria-based therapeutics-is through the execution of clinical trials. While specific site counts aren't public as of late 2025, the company's pipeline progress dictates channel activity. The lead compound, CB4211, was previously in a Phase 1a/1b trial for NASH and obesity, and preclinical programs like CB5138 Analogs target fibrotic diseases like idiopathic pulmonary fibrosis. The operational channel relies on established relationships with Clinical Research Organizations (CROs) to manage these sites.

The broader industry context shows that in 2025, the global CRO industry is projected to reach $90 billion by year-end, driven by decentralized trial innovations. This means CohBar, Inc.'s engagement with sites is likely digitized, utilizing integrated eClinical ecosystems where the use of digital tools by clinical trial sites rose to 81% in 2022, a trend that has certainly accelerated. The company's ability to secure high-quality sites is paramount, as sponsors avoid sites that repeatedly underperform.

Pipeline Program	Indication Focus	Last Known Development Stage (Pre-2025)
CB4211	NASH and Obesity	Phase 1b
CB5138 Analogs	Idiopathic Pulmonary Fibrosis (IPF)	Preclinical
IFx-Hu2.0 (via Morphogenesis merger)	Merkel Cell Carcinoma (MCC) and cSCC	Phase 1b Positive Results (as of June 2023)

Scientific publications and medical conferences

Scientific dissemination is a critical channel for building credibility and attracting future partners. This involves publishing data in peer-reviewed journals and presenting at key medical conferences. The company's Mito+ platform and peptide discoveries must be validated through this channel to support the development of drug candidates.

Historically, data from the CB4211 study were presented at the American Association for the Study of Liver Disease (AASLD) 2021 Liver Meeting®. The channel strategy is to use these scientific forums to communicate progress on their pipeline, which includes over 100 mitochondrial derived peptides and over 1,000 analogs discovered to date. The success of this channel directly influences the attractiveness of the licensing channel.

• Data presentation at major medical society meetings.
• Publication in high-impact, peer-reviewed journals.
• Communication of intellectual property coverage, including over 65 patent applications filed historically.
• Presentations to key opinion leaders in mitochondrial biology.

Investor presentations and SEC filings

For a publicly traded entity, regulatory filings and investor outreach are the formal channels for communicating financial health and strategic direction. As of early 2025, CohBar, Inc. was trading on the OTC market, having transitioned from NASDAQ. The stock price on January 06, 2025, was $0.41, with a reported Market Cap of $1.19M, classifying it as a Micro Cap. By February 7, 2025, the price had moved to $0.88.

The most recent definitive financial data available reflects a period before the full integration following the merger agreement with Morphogenesis, Inc. The channel for investor information relies on timely 10-K and 10-Q filings, which provide the official record of cash reserves and operating expenses. The shift in listing venue itself is a key communication point to the investment community.

Metric	Value/Status	Date Reference
Stock Price (Low Reference)	$0.41 USD	January 06, 2025
Market Capitalization	$1.19M USD	January 06, 2025
Exchange Listing	OTC	As of January 2025
Historical NME Revenue Driver	70 percent from external sourcing (Industry Trend)	Since 2018

Future pharmaceutical licensing partners

This is arguably the most crucial external channel for a clinical-stage company like CohBar, Inc. The strategy explicitly involves advancing drug candidates through strategic partnerships with larger biopharmaceutical companies. The merger with Morphogenesis, Inc. itself represents a major strategic alignment, but the pipeline development still requires external validation and commercialization reach.

The industry trend in 2025 reinforces this channel's importance: large pharma companies are becoming more selective regarding early-stage R&D, making them increasingly reliant on external innovation and clinical-stage dealmaking to fill their pipelines. CohBar, Inc.'s intellectual property portfolio, covering over 100 natural peptides and analogs, serves as the primary asset being channeled to these potential partners. The goal is to secure deals that capture maximum value, whether through internal development or partnership.

• Targeting larger biopharmaceutical companies for in-licensing.
• Leveraging strong IP coverage to enhance deal attractiveness.
• Focusing on clinical-stage assets for potential partnerships.
• Utilizing scientific conference presence to network with potential dealmakers.

Finance: draft 13-week cash view by Friday.

CohBar, Inc. (CWBR) - Canvas Business Model: Customer Segments

You're looking at the core groups that CohBar, Inc. (CWBR) needs to engage to move its pipeline forward, especially given its clinical-stage status and recent corporate activity. Honestly, for a company like this, the customer segments aren't just end-users; they are critical partners and funders.

Patients with advanced, solid tumors resistant to standard therapies

This segment represents the ultimate beneficiaries for the preclinical cancer assets, such as the MBT3 Analogs for cancer immunotherapy and MBT5 Analogs for CXCR4-related cancer. The sheer scale of the patient population needing novel options is substantial, grounding the commercial potential. In the United States in 2025, there are approximately 2,041,910 new cancer diagnoses projected to occur. Solid tumors represent around 85% of these cases. For context on the need for advanced therapies, the global solid tumor therapeutics market size stood at USD 207.29 billion in 2025. The U.S. solid tumor cancer treatment market size was evaluated at USD 1.32 billion in 2024.

The need for novel approaches is underscored by the fact that for certain cancers, like chronic myeloid leukemia, drug resistance occurs in 5% to 10% of patients. The patient pool for CohBar, Inc. is defined by the failure of existing lines of therapy, which is a significant subset of the total diagnosed population.

Oncologists and specialized cancer treatment centers

These are the clinical gatekeepers who will ultimately test and prescribe any successful therapeutic. Their focus is on centers treating complex, resistant cases. As of 2025, there are approximately 25,419 oncologists actively practicing in the United States. Within this group, the number of physicians tracked specializing in Hematology/oncology is 11,937. The demand for these specialists is high, with projections indicating a total shortfall of 2,258 full-time equivalent clinical care FTEs across the U.S. by 2025.

• The majority of oncologists, about 67.5%, work exclusively in urban settings.
• The density of medical and hematology oncologists relative to the aging population is decreasing.
• The total number of new cancer cases in the U.S. in 2025 is estimated at 2,041,910.

Large pharmaceutical companies seeking late-stage oncology assets

These entities are the primary potential acquirers or partners for CohBar, Inc.'s pipeline assets, especially if they advance past preclinical stages, like the CB4211 (NASH/Obesity) or CB5138 Analogs (IPF). Big Pharma is actively seeking bolt-on deals, particularly in oncology. For instance, one major oncology deal in June 2025 between Bristol Myers Squibb and BioNTech had a total value of $11 billion, including $1.5 billion upfront. Another illustrative deal in the first half of 2025 involved a value of approximately $14.6 billion. Furthermore, approximately 85% of China out-licensing deals are focused on oncology, showing a global appetite for external oncology innovation.

The industry holds significant capital, with biopharma companies holding US$1.3 trillion in dealmaking Firepower as of early 2025, though the focus has shifted to smaller, smarter deals.

Institutional and retail investors funding the development stage

This segment provides the necessary capital to fund the multi-year, high-cost clinical development process. For CohBar, Inc., as of November 30, 2025, the stock price was $0.41, and the market capitalization as of January 16, 2025, was $1.19M. The company, which employs around 9 to 10 full-time employees, has generated over 1,000 analogs from its discovery platform. The company's stock trades on the OTCMKTS exchange following a delisting notice in November 2023.

Financial Metric	Value/Amount	Date Context
Stock Price	$0.41	November 30, 2025
Market Capitalization	$1.19M	January 16, 2025
Full Time Employees	9	2025 Data
Total Mitochondrial Derived Peptide Analogs Generated	Over 1,000	Preclinical Data
Total Oncology Deals Value (Largest Example 1H 2025)	$11 billion	June 2025

The company's ability to attract funding is directly tied to the progression of its lead candidates, CB4211 and CB5138 Analogs, through clinical milestones.

CohBar, Inc. (CWBR) - Canvas Business Model: Cost Structure

You're looking at the core expenses CohBar, Inc. (CWBR) faces to keep its pipeline moving, which is typical for a clinical-stage biotech. The cost structure is heavily weighted toward discovery and development, meaning cash burn is the primary financial reality until a partnership or commercial success hits.

High Research and Development (R&D) expenses form the largest component of the operating cost structure. This covers everything from preclinical work to managing ongoing clinical trials. For instance, R&D spending for the first quarter of 2024 was reported at around $1.8 million.

Clinical trial costs are embedded within the R&D spend and are highly variable based on the phase and complexity of the drug candidate, such as CB5138-3 targeting Idiopathic Pulmonary Fibrosis (IPF). While the Q1 2024 R&D was $1.8 million, historical data shows quarterly R&D costs fluctuating, such as $1.5 million in Q1 2022 and $2.2 million in Q4 2022 [cite: 5 from previous search].

General and administrative (G&A) overhead covers the necessary operational expenses outside of the lab and trials. This includes executive salaries, rent, and general corporate functions. The latest available quarterly G&A figure we have is from mid-2023, where it stood at $4.3 million for the quarter ended June 30, 2023 [cite: 2 from previous search].

Intellectual property maintenance and legal fees are a distinct, recurring cost necessary to defend and maintain the company's competitive moat. These costs are often bundled into G&A, but specific maintenance fees are required to keep patent families active. For example, aggregate annual maintenance fees paid to licensors for two specific agreements totaled $87,500 in 2022 [cite: 1 from previous search].

Here's a quick look at how some of these key operating expenses have tracked quarterly, showing the variability in R&D versus the more stable G&A base:

Period	R&D Expense (Approximate)	G&A Expense (Approximate)
Q1 2024	$1.8 million	Data not explicitly available for this quarter
Q2 2023	$0.17862 million	$4.3 million [cite: 2 from previous search]
Q1 2023	$1.0 million	$1.3 million [cite: 2 from previous search]
Q4 2022	$2.2 million	$1.7 million [cite: 2 from previous search]

The primary cost drivers CohBar, Inc. (CWBR) manages are:

• Funding IND-enabling studies and formulation work.
• Managing patent prosecution and international filings.
• Covering fixed costs like executive compensation and facilities.
• Paying annual patent maintenance fees, such as the $87,500 paid across key licenses in 2022 [cite: 1 from previous search].

What this estimate hides is the potential for large, one-time legal expenses related to litigation or significant IP defense, which would spike the G&A line item.

CohBar, Inc. (CWBR) - Canvas Business Model: Revenue Streams

You're looking at the revenue side of CohBar, Inc. (CWBR) as of late 2025, and honestly, it's what you'd expect for a company deep in clinical development. The model isn't built on selling anything yet; it's built on capital preservation and hitting milestones.

Currently $0 from core product sales (pre-commercial stage)

As of the latest fiscal year fundamentals, CohBar, Inc.'s reported revenue from core operations is $0. This is the reality for a pre-commercial biotech focused on advancing its pipeline, specifically the lead asset, IFx-Hu2.0. Since IFx-Hu2.0 is in a Phase 3 accelerated approval trial as of mid-2025, product sales revenue is not yet a factor in the current model.

Future milestone payments from potential licensing agreements

The near-term potential for non-dilutive cash flow hinges on securing a licensing agreement for IFx-Hu2.0 or other pipeline assets. These deals typically structure payments around specific achievements:

• Non-refundable upfront payments upon signing.
• Development milestone payments tied to clinical trial completions.
• Regulatory milestone payments upon FDA approval.

Future royalties on net sales of IFx-Hu2.0

Once IFx-Hu2.0 potentially gains market approval-it's being evaluated in a Phase 3 trial for advanced or metastatic Merkel cell carcinoma (MCC) as of June 2025-the long-term revenue stream will shift to royalties. This is the ultimate goal of the development strategy.

Here's a quick look at the financial context supporting the current operations:

Financial Metric	Amount (TTM)	Implication
Revenue from Core Operations	$0	No product sales; entirely reliant on financing.
Net Income (Profit/Loss)	-$12.55 million	Represents the cash burn rate that financing must cover.
Market Capitalization (Early 2025 Estimate)	$1.19 million	Highlights the high reliance on external capital given the low valuation base.

Equity financing and capital raises to cover the TTM net loss of -$12.55 million

Since product revenue is zero, the current financial lifeline for CohBar, Inc. is its ability to raise capital to fund its operations and clinical trials. The Trailing Twelve Months (TTM) net loss of -$12.55 million must be covered by these financing activities to maintain the runway. This is the primary, current source of operational funding.

The company's cash generation strategy, therefore, looks like this:

• Primary Funding Source: Issuance of common stock and warrants in public offerings.
• Secondary Potential: Upfront payments from any pre-commercial licensing deals.
• Key Risk: Dilution of existing shareholder equity with each capital raise.

Finance: draft 13-week cash view by Friday.